MiniMed Group, Inc. MMED
MiniMed Group, Inc. (Nasdaq: MMED) is a cardio-renal-metabolic medical device company. Its next catalyst on record is MiniMed Flex: Commercial launch in applicable European markets (November 2026).
Upcoming catalysts
- November 2026MiniMed Flex — Commercial launch in applicable European markets
We expect this approval to support the commercial launch of MiniMed Flex in applicable European markets starting in November 2026.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MiniMed 780G AID system | diabetes | — | NA_NON_THERAPEUTIC |
| MiniMed Flex | diabetes | — | NA_NON_THERAPEUTIC |
| MiniMed Go Smart MDI / InPen | diabetes | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
- DexCom, Inc. DXCM
- Penumbra Inc PEN
- Insulet Corp PODD
- Heartflow, Inc. HTFL
- iRhythm Holdings, Inc. IRTC
- Pulse Biosciences, Inc. PLSE
- AtriCure, Inc. ATRC
- LeMaitre Vascular, Inc. LMAT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.